2 January 2015 - Idelalisib (trade name Zydelig) has been available since September 2014 for use by patients with follicular lymphoma or chronic lymphocytic leukaemia. The Institute for Quality and Efficiency in Health Care (IQWiG) has determined whether this drug compared with the appropriate comparator therapy offers an additional benefit. An additional benefit for either of indications is not present because the manufacturer has submitted no suitable data.

For more details, go to: https://www.iqwig.de/de/presse/pressemitteilungen/pressemitteilungen/zusatznutzen-von-idelalisib-ist-nicht-belegt.6516.html?&et_cid=4&et_lid=%25208 [German]